Literature DB >> 2425749

[Side effects of peplomycin].

Y Araki, K Tamura, M Seita.   

Abstract

Twenty-three patients with squamous cell carcinoma were treated with a combination chemotherapy consisting of cisplatin, vincristine, and peplomycin. Overall response rate was over 70% including complete disappearance of tumors in one patient. Peplomycin was given by continuous i.v. or s.c. infusion using a micro-infusion pump. All the patients experienced some degree of nausea, vomiting, and hair loss. Phlebitis and induration of injection sites with subsequent local pigmentation were frequently encountered. Nausea and vomiting were caused mainly by cisplatin, but more than 60% of the patients experienced transient increase of anorexia or nausea in the period of peplomycin administration. Eruption with skin excoriation or pigmentation along scratch dermatitis were seen in 5 patients. These side effects were well tolerated, and high fever which is commonly observed in one-shot therapy did not develop in any patient. Pulmonary fibrosis was also not seen. Peplomycin should be given by low-dose continuous infusion because of its low toxicity and comparable antineoplastic activity to one-shot therapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2425749

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  3 in total

1.  Bleomycin-induced Flagellate Erythema: A Rare and Unique Drug Rash.

Authors:  K H Changal; H Raina; Q H Changal; M Raina
Journal:  West Indian Med J       Date:  2014-08-29       Impact factor: 0.171

2.  Trastuzumab-Associated Flagellate Erythema: Report in a Woman with Metastatic Breast Cancer and Review of Antineoplastic Therapy-Induced Flagellate Dermatoses.

Authors:  Philip R Cohen
Journal:  Dermatol Ther (Heidelb)       Date:  2015-10-27

3.  Unusual and Interesting Adverse Cutaneous Drug Reactions.

Authors:  Vaishali Masatkar; Ashok Nagure; Lalit Kumar Gupta
Journal:  Indian J Dermatol       Date:  2018 Mar-Apr       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.